Emergence of a ribotype 244 strain of clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain

Clinical Infectious Diseases

Volumn 58, Issue 12, 2014, Pages 1723-1730

  Lim, Sze K ^a   Stuart, Rhonda L ^a,b   MacKin, Kate E ^b   Carter, Glen P ^b   Kotsanas, Despina ^a   Francis, Michelle J ^a   Easton, Marion ^c   Dimovski, Karolina ^c   Elliott, Briony ^d   Riley, Thomas V ^d,e   Hogg, Geoff ^c   Paul, Eldho ^f   Korman, Tony M ^a,b   Seemann, Torsten ^b   Stinear, Timothy P ^c   Lyras, Dena ^b   Jenkin, Grant A ^a,b,c  

^a SOUTHERN HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e Path West Laboratory Medicine   (Australia)

^f Centre of Cardiovascular Research Education in Therapeutics School of Public Health and Preventive Medicine   (Australia)

Author keywords

Clostridium difficile; toxin B; virulence; whole genome sequencing

Indexed keywords

BACTERIAL TOXIN; METRONIDAZOLE; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TOXIN B; UNCLASSIFIED DRUG; VANCOMYCIN; BACTERIAL PROTEIN; REPRESSOR PROTEIN; TCDC PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM SORDELLII; COHORT ANALYSIS; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; EPIDEMIC; FEMALE; GENE DELETION; GENE LOCUS; GENE SEQUENCE; HUMAN; MALE; MICROBIOLOGICAL EXAMINATION; PATHOGENICITY; PHYLOGENOMICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TOXIN ANALYSIS; VERO CELL LINE; BACTERIAL GENOME; COMMUNICABLE DISEASES, EMERGING; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FRAMESHIFT MUTATION; GENETICS; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PHYLOGENY; RIBOTYPING; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FRAMESHIFT MUTATION; GENOME, BACTERIAL; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; RIBOTYPING; SEVERITY OF ILLNESS INDEX;

EID: 84901778651     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu203     Document Type: Article

References (40)

1. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
2. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
3. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12(suppl 6): 2-18.
4. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50:194-201.
5. MacCannell DR, Louie TJ, Gregson DB, et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 2006; 44:2147-52.
6. Carter GP, Douce GR, Govind R, et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog 2011; 7:e1002317.
7. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47:1162-70.
8. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-49.
9. Wilcox MH, Shetty N, Fawley WN, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis 2012; 55:1056-63.
10. Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012; 55:1661-8.
11. Walker AS, Eyre DW, Wyllie DH, et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013; 56:1589-600.
12. Stabler RA, Dawson LF, Valiente E, et al. Macro and micro diversity of Clostridium difficile isolates from diverse sources and geographical locations. PLoS One 2012; 7:e31559.
13. He M, Sebaihia M, Lawley TD, et al. Evolutionary dynamics of Clostridium difficile over short and long time scales. Proc Natl Acad Sci USA 2010; 107:7527-32.
14. Kok J, Wang Q, Thomas LC, Gilbert GL. Presumptive identification of Clostridium difficile strain 027/NAP1/BI on Cepheid Xpert: interpret with caution. J Clin Microbiol 2011; 49:3719-21.
15. Richards M, Knox J, Elliott B, et al. Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia. Med J Aust 2011; 194:369-71.
16. Ferguson JK, Cheng AC, Gilbert GL, et al. Clostridium difficile laboratory testing in Australia and New Zealand: national survey results and Australasian Society for Infectious Diseases recommendations for best practice. Pathology 2011; 43:482-7.
17. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15:1067-79.
18. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
19. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
20. Perry JD, Asir K, Halimi D, et al. Evaluation of a chromogenic culture medium for isolation of Clostridium difficile within 24 hours. J Clin Microbiol 2010; 48:3852-8.
21. Lemee L, Dhalluin A, Testelin S, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004; 42:5710-4.
22. O'Connor JR, Lyras D, Farrow KA, et al. Construction and analysis of chromosomal Clostridium difficile mutants. Mol Microbiol 2006; 61:1335-51.
23. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004; 42:1933-9.
24. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002; 40:3470-5.
25. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998; 36: 2240-7.
26. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37:461-3.
27. Rothberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011; 475: 348-52.
28. Eyre DW, Cule ML, Wilson DJ, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 2013; 369:1195-205.
29. Stabler RA, Gerding DN, Songer JG, et al. Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol 2006; 188:7297-305.
30. Griffiths D, Fawley W, Kachrimanidou M, et al. Multilocus sequence typing of Clostridium difficile. J Clin Microbiol 2010; 48:770-8.
31. Spigaglia P, Barbanti F, Mastrantonio P, et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 2008; 57(pt 6): 784-9.
32. Blake JE, Mitsikosta F, Metcalfe MA. Immunological detection and cytotoxic properties of toxins from toxin A-positive, toxin B-positive Clostridium difficile variants. J Med Microbiol 2004; 53(pt 3): 197-205.
33. Rupnik M. Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol Rev 2008; 32:541-55.
34. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-36.
35. Drudy D, Fanning S, Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 2007; 11:5-10.
36. De Almeida MN, Heffernan H, Dervan A, et al. Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCRribotype 244. N Z Med J 2013; 126:9-14.
37. Lanis JM, Barua S, Ballard JD. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog 2010; 6:e1001061.
38. Gerding DN, Johnson S, Rupnik M, Aktories K. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes 2013; 5:1-13.
39. Goldenberg SD, French GL. Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. J Infect 2011; 62:355-62.
40. Rupnik M, Widmer A, Zimmermann O, Eckert C, Barbut F. Clostridium difficile toxinotype V, ribotype 078, in animals and humans. J Clin Microbiol 2008; 46:2146.